Current Price
Psyence Biomedical Ltd. is a leading innovator in the psychedelic biopharmaceutical industry, dedicated to developing psilocybin-based therapies for pressing mental health conditions such as anxiety and depression. The c...|
e.g. Promoter holding
Loading chart...
Analyst consensus EPS and Revenue forecasts.
Earnings estimates are not available for this company.
| S.No. | Name | Symbol | Market Cap | P/E | P/B | Profit Margin | Op. Margin | ROE | Rev. Growth |
|---|---|---|---|---|---|---|---|---|---|
| 1. | RRevolution... | RVMDW | — | — | — | — | -853.00% | -93.60% | — |
| 2. | KPasithea T... | KTTAW | — | — | — | — | — | -65.50% | — |
| 3. | EEstrella I... | ESLAW | — | — | — | — | — | — | — |
| 4. | CConduit Ph... | CDTTW | — | — | — | — | — | -69.70% | — |
| 5. | AAlumis Inc | ALMS | $727.00M | — | 1.92 | — | -5,938.00% | -110.90% | -7.70% |
Consolidated Figures in Millions / View Standalone.
| Quarter (M) | Dec 22 | Mar 23 | Jun 23 | Sep 23 | Dec 23 | Sep 24 | Dec 24 | Sep 25 |
|---|---|---|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - | - | - | - | - |
| 0.51 | 0.77 | 0.51 | 0.18 | 0.63 | 1.16 | 1.16 | 1.51 | |
EBIT | -0.51 | -1.04 | -0.51 | -0.17 | -0.63 | -1.16 | -1.16 | -1.51 |
OPM % | - | - | - | - | - | - | - | - |
Non-Operating Income | 0 | 0 | 0 | -0.13 | 0 | 1.3 | 0 | 0.75 |
PBT | 2.25 | -0.02 | -0.06 | -0.31 | -24.76 | 0.14 | 0.14 | -0.75 |
Income Tax | 0 | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | - | -2.76% | - | - | - | - |
Net Income | 2.25 | -0.02 | -0.06 | -0.31 | -24.76 | 0.14 | 0.14 | -0.75 |
NPM % | - | - | - | - | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 | 0 |
COGS | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Gross Profit % | - | - | - | - | - |
| 1.86 | 3.23 | 46.69 | 3.66 | 6.24 | |
EBIT | -1.85 | -3.23 | -45.81 | -3.66 | -6.24 |
OPM % | - | - | - | - | - |
Non-Operating Income | -0 | 0.03 | -5.35 | 4.67 | -0.7 |
PBT | -1.86 | -3.21 | -51.16 | 1.01 | -6.94 |
Income Tax | 0 | 0 | 0 | 0 | 0 |
Tax Rate % | - | - | 0% | - | - |
Net Income | -1.86 | -3.21 | -51.16 | 1.01 | -6.94 |
NPM % | - | - | - | - | - |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|---|
| 4.75 | 1.75 | 1.33 | 0.73 | 6.14 | 7.44 | |
| 0 | 0 | 0 | 0 | 0.74 | 8.45 | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
| 0.15 | 0.08 | 0.26 | 0.72 | 0.43 | 1.67 | |
| 0 | 0 | 0 | -0.32 | 0.01 | 0.01 | |
Total Assets | 4.9 | 1.83 | 1.59 | 1.13 | 7.32 | 17.57 |
| 0 | 0 | 0 | 46.13 | 61.75 | 78.75 | |
| 4.8 | 1.7 | -0.2 | -57.1 | -55.03 | -61.8 | |
| 0 | 0 | 0 | 10.45 | 0 | 0 | |
| 0.1 | 0.13 | 1.79 | 1.66 | 0.59 | 0.62 | |
| 0 | 0 | 0 | 0 | 0 | 0 | |
Total Liabilities | 4.9 | 1.83 | 1.59 | 1.13 | 7.32 | 17.57 |
Consolidated Figures in Millions / View Standalone.
| Period (M) | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|
| -1.4 | -1.59 | -2.95 | -3.73 | -8.14 | |
| -0.03 | 0 | -0.01 | -0.02 | -4.51 | |
| -1.63 | 1.17 | 2.35 | 9.15 | 13.96 | |
Net CFNet Cash Flow | -3.06 | -0.42 | -0.6 | 5.4 | 1.31 |
FCFFree Cash Flow | -1.4 | -1.59 | -2.95 | -3.74 | -8.64 |
Financial ratios and valuation metrics by fiscal year.
| Period | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 | Dec 2026 |
|---|---|---|---|---|---|---|
| - | -57.2% | -427.6% | 915.8% | -47.6% | -58.6% | |
| - | - | - | -0.95 | - | - | |
| 48.50 | 13.90 | 0.89 | 0.09 | 11.04 | 14.62 | |
| - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Cash Conversion | - | 0.75 | 0.50 | 0.06 | -3.69 | 1.17 |
Payout Ratio | - | - | - | - | - | - |
| - | - | - | - | - | - | |
| - | - | - | - | - | - | |
| - | - | - | - | - | - | |
| - | 2.00 | 2.00 | 3.00 | 4.00 | 2.00 | |
| - | - | - | - | - | - | |
| - | 0.00 | - | - | 40.00 | 0.00 | |
| - | - | - | - | - | - |
Note: These ratios and scores are calculated using publicly available financial data and may differ from other sources. Users are advised to verify calculations independently using SEC filings or other official sources before making investment decisions.
Who owns Psyence Biomedical Ltd - Warrants (25/01/2029), from SEC filings
Who owns the company, quarter by quarter
Calendar quarters (13F report dates). Jun 2026 can still change as late 13F amendments arrive.
| Shares held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | QoQ |
|---|---|---|---|---|---|---|---|---|---|
InsidersInsiders | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1.6M | 1.8M | 1.8M | 2.1M | 2.1M | 2.1M | 2.1M | 2.1M | +14.6K | |
| 4.7M | 4.0M | 3.9M | 4.0M | 3.6M | 3.5M | 3.4M | 3.4M | +83.4K | |
Govt.Government & pensions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of institutional holders | 23 | 22 | 23 | 22 | 21 | 19 | 20 | 26 | +6 |
Insiders = officers, directors and 10% owners (Forms 3/4/5). Foreign vs US = the 13F manager's registered address. Government = sovereign funds, central banks and public pensions. Public includes retail investors and funds below the $100M 13F threshold. Named holders are the largest 13F filers each quarter; shares outstanding come from the 10-K / 10-Q cover page.
| Holder | Type | Based in | Shares | % of class | Latest filing |
|---|---|---|---|---|---|
| Investment company | DE | 258,538 | 6.78% | SC 13G · 5 Oct 2026 | |
| Individual | X1 | 59,750 | 2.61% | SC 13G/A · 10 Jun 2026 | |
| Other | DE | 0 | 0.00% | SC 13G/A · 15 May 2025 | |
| Investment adviser | DE | 237,768 | 4.99% | SC 13G/A · 14 May 2025 |
Anyone owning more than 5% must file a Schedule 13D (active) or 13G (passive). Structured filings since December 2024; a holder that drops below 5% files an exit amendment. 13F still covers them in the shareholding table.
| Settlement date | Short shares | Change | Days to cover | Relative size |
|---|---|---|---|---|
| 30 Oct 2026 | 19,925 | +13.0% | 2.68 | |
| 15 Oct 2026 | 17,628 | -1.7% | 1.00 | |
| 30 Sep 2026 | 17,933 | +11.5% | 1.00 | |
| 15 Sep 2026 | 16,090 | -16.4% | 1.00 | |
| 31 Aug 2026 | 19,253 | -20.6% | 1.00 | |
| 14 Aug 2026 | 24,244 | +79.3% | 1.23 | |
| 31 Jul 2026 | 13,525 | +0.2% | 1.30 | |
| 15 Jul 2026 | 13,498 | +0.6% | 7.57 | |
| 30 Jun 2026 | 13,416 | +0.9% | 1.00 | |
| 15 Jun 2026 | 13,290 | -7.0% | 1.00 | |
| 29 May 2026 | 14,291 | -6.6% | 1.00 | |
| 15 May 2026 | 15,296 | -14.8% | 2.08 | |
| 30 Apr 2026 | 17,956 | +1.7% | 1.00 | |
| 15 Apr 2026 | 17,650 | +1.1% | 4.60 | |
| 31 Mar 2026 | 17,460 | 0.0% | 1.44 | |
| 13 Mar 2026 | 17,460 | -26.0% | 1.10 | |
| 27 Feb 2026 | 23,603 | -15.8% | 2.52 | |
| 13 Feb 2026 | 28,030 | -17.5% | 1.18 | |
| 30 Jan 2026 | 33,973 | +5.8% | 1.00 | |
| 15 Jan 2026 | 32,110 | +1.0% | 1.14 | |
| 31 Dec 2025 | 31,777 | +9.9% | 1.81 | |
| 15 Dec 2025 | 28,904 | -13.8% | 1.00 | |
| 28 Nov 2025 | 33,546 | +10.7% | 1.00 | |
| 14 Nov 2025 | 30,308 | -5.9% | 2.79 |
FINRA consolidated short interest, reported twice a month for every US listing.
Psyence Biomedical Ltd - Warrants (25/01/2029)'s SEC filings and earnings call transcripts
What recent news says about Psyence Biomedical Ltd - Warrants (25/01/2029), scored for sentiment.